CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NatK project investigates chemotherapy resistance in triple negative breast cancer by focusing on natural killer cells. It aims to identify immune signatures of resistance and develop strategies to enhance NK cell activity against resistant tumors, utilizing advanced technologies like spatial transcriptomics and pa…
Chemotherapy resistance remains a major challenge in cancer treatment, often leading to poor patient outcomes.
NatK aims to (1) identify predictive signature of chemoresistance and (2) develop innovative therapeutic strategies to overcome it, using triple negative breast cancer (TNBC) as a model.
The focus is on natural killer (NK) cells, hypothesising that reactivating these cells could enhance their cytotoxicity against chemoresistant tumours.
State-of-the-art 10X Visium spatial transcriptomi…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
